IRD news

Latest 3 stories · newest Oct 15, 2026

IRD
Opus Gen presents positive BEST1 and LCA5 data

Opus Gen reported positive clinical outcomes for OPGx-BEST1 and sustained visual improvements for OPGx-LCA5, supporting pipeline progression and upcoming Phase 3 dosing, impacting the clinical-stage gene therapy sector.

Earnings|Guidance|Leadership|Restructuring|Regulatory|Legal|Cyber|Offering|Bankruptcy|Other Oct 15, 2026 sentiment +0.50 SEC filing ↗
IRD
Opus Genetics Shares Rocket 70% on Gene Therapy Trial Success

Opus Genetics reported positive results for OPGx-BEST1 in a Phase 1/2 trial, meeting FDA endpoints and triggering a surge in stock price that highlights the market's appetite for biotech breakthroughs.

Earnings Sep 9, 2026 sentiment +0.70 SEC filing ↗
IRD
Opus Genetics advances five gene therapy programs with four clinical data readouts expected in 2027

Opus Genetics highlighted its expanding pipeline for inherited retinal diseases with three new programs entering clinical testing over the next 12-18 months and cash runway extending into 2029. The company's first-mover advantage across multiple rare disease indications and potential for Priority Re…

Other Jun 16, 2026 sentiment +0.75 SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same IRD feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/IRD/newsSTART FREE